The blood-based test by Astrin Biosciences shows high sensitivity and specificity across cancer stages and subtypes, ...
The patient received trifluridine/tipiracil plus bevacizumab as third-line therapy; is currently on month 4 of treatment.​ ...
Orca-T immunotherapy shows promising results in improving survival and reducing complications in patients with hematologic ...
A promising trial reveals pumitamig combined with chemotherapy shows high response rates, suggesting potential benefits for ...
A combination of the antibody-drug conjugate enfortumab vedotin (Padcev) and the PD-1 inhibitor pembrolizumab (Keytruda) ...
Schmid detailed the rationale of combining pumitamig and chemotherapy and how the combination can aid patients in the first ...
PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising ...
Dr. Marc S. Hoffmann reveals promising 6-year results from the SEQUOIA study on zanubrutinib for chronic lymphocytic leukemia ...
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, ...
Michael Wang, MD, professor at The University of Texas MD Anderson Cancer Center, details the rationale for a long-term ...
The FDA has granted regular approval to rucaparib (Rubraca) for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant ...
During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback